AGEN

Agenus
AGEN

3.10 USD
+0.12
4.03%
At close Updated Mar 13, 4:00 PM EDT
Pre-market
After hours
3.12
+0.02
0.65%
1 day
4.03%
5 days
5.08%
1 month
6.16%
3 months
-16.44%
6 months
-30.34%
Year to date
-4.02%
1 year
84.52%
5 years
-95.35%
10 years
-96.08%
 

About: Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).

Employees: 316

Healthcare Biotechnology
0
Funds holding %
of 8,077 funds
Explore Fund Trends
–
Analysts bullish %
See Analyst Outlook
0
Positive news %
Check Journalist POV
Price charts implemented using Lightweight Charts™